Rituximab products (Revised)
This is a historical Humana Medicaid prior authorization policy for rituximab products (Rituxan, Ruxience, Riabni, Truxima) effective January 1, 2026, revised October 28, 2026, covering Kentucky and South Carolina Medicaid members. The policy requires prior authorization for all listed indications and establishes clinical criteria including mandatory use of generic/biosimilar alternatives (Ruxience or Riabni) first, with branded products (Rituxan or Truxima) approved only if the member has intolerance or contraindication to the alternatives. The policy was discovered on November 3, 2026, but both the effective date (January 1, 2026) and revision date (October 28, 2026) are in the past relative to the analysis date; the practice should verify current applicability with Humana's online policy portal before implementing.